Cancer: Principles & Practice of Oncology Annual Advances in Oncology

by DeVita, Jr., Vincent T.; Lawrence, Theodore S.; Rosenberg, Steven A.

• ISBN13: 9781451142693
• ISBN10: 1451142692
• Edition: 1st
• Format: Hardcover
• Copyright: 2011-06-16
• Publisher: LWW

Summary

Announcing the second volume of DeVita, Lawrence and Rosenberg's groundbreaking series, Cancer: Principles & Practice of Oncology—Annual Advances in Oncology. This series of annual volumes focuses on the most significant changes in oncologic research and practice that have taken place during the preceding year. Each volume identifies scientific and clinical areas in oncology that are rapidly changing and show a high potential for affecting the management of cancer patients in the future. These areas may reflect current controversies in oncology and every effort is made to provide clear direction for the practicing oncologist.

Table of Contents

Section Editors iii Contributing Authors iv Preface xv P TRI ART 1:PLE-NEGATIVE BREAST CANCER1. Epidemiology to Treatment.........................1 Triple-Negative Breast Cancer: FromCLIFFOR D A. HUDIS2. and Basal Breast Cancers?..........................3 What is the Difference between Triple-NegativeMELANIE D. SEAL AND STEPHEN K. CHIA3. 10,000 Feet..............................................8 Triple-Negative Breast Cancers: A View fromMAN DIRA RAY AND BLASE N. POLITE4. Triple-Negative and Basal-Like Breast Cancer: Promising Clinical Target or Only a Marker?......................................14 Epidermal Growth Factor Receptor inMONIKA L. BURNESS, TATYANA A. GRUSHKO, AN DOLUFUNMILAYO I. OLO PADE5. Antiangiogenic Agents ............................. 24 Triple-Negative Breast Cancer: Role ofSALLY GREENBERG AN D HOPE S. RUGO6. Tumor Suppression: A Repair-Centric Perspective.............................................30 BRCA Gene Structure and Function inCONLETH G. MUR PHY ANDMARY ELLEN MOYNAHAN 7. Triple-Negative Breast Cancer...................39 Poly (ADP-Ribose) Polymerase Inhibitors inELIZABETH A. COMEN AN D MARK ROBSON8. Specific Chemotherapy Agents...................44 Triple-Negative Breast Cancer: Role ofSTEVEN J. ISAKOFF 9. Androgen Receptor ................................. 53 Triple-Negative Breast Cancer: Role of theAYCA GUCAL P AND TIFFANY A. TRAINAP LOCAL THERA OF LIVER METASTASES ART 2:PIES IN THE TREATMENT10. Treatment of Liver Cancer........................57 Introduction to Local Therapies in theWILLIAM D. ENSMINGER AND ALFRED E. CHANG11. Hepatic Imaging for Metastatic Disease.......59P ETER S. LIU AND ISAAC R. FRANCIS12. Metastasis: Evolving Role in the Setting of Improving Systemic Therapies and Ablative Treatments in the 21st Century..................69 Surgical Treatment of Hepatic ColorectalKAORI ITO, ANAN AN D GOVINDARAJAN, HIROMICHI ITO,D YUMAN FONG13. Hepatic Malignancies...............................77 Thermal Ablative Therapies for SecondarySKYE C. MAYO AN D TIMOTHY M. PAWLIK14. Liver Cancer...........................................84 Focused Ultrasound as a Local Therapy forKRISZTINA FISCHER, WLA DYSLAW GEDROYC, ANDFERENC A. JOLESZ 15. Patients with Resectable Liver Metastases....91 The Role of Chemotherapy in ManagingTHORVAR MICHAEL L. KEN DUR R. HALFDANARSON,DRICK, AND AXEL GROTHEY16. via the Operative and Percutaneous Techniques for Patients with Isolated and Unresectable Liver Metastases...................98 Development of Isolated Hepatic PerfusionH. RICHAR D ALEXANDER, JR., ANDCAROLINE C. BUTLER 17. Infusion Pumps.....................................108 Implanted Hepatic ArterialMARGARET K. CALLAHAN AN DNANCY E. KEMENY 18. Management of Liver Metastases ............. 116 Emerging Role of Radiotherapy in theANAN D SWAMINATH AND LAURA A. DAWSON19. Metastatic Liver Cancer..........................122 Chemoembolization for Primary andELENI LIA PI AND JEAN-FRANCOIS H. GESCHWIND20. for Primary and Metastatic Hepatic Malignancies ........................................129 Radioembolization (Yttrium-90 Microspheres)AN DREW S. KENNEDY AND RIAD SALEMP CHEMOTHERA CANCER ART 3:PY FOR COLORECTAL21. Colorectal Cancer..................................143 Introduction to Chemotherapy forE DWARD CHU22. Biology of Colorectal Cancer...................144MUHAMMA D WASIF SAIF AND EDWARD CHU23. Advances and Future Directions...............150 Stage II and Stage III Colon Cancer: TreatmentBENO\u00c2IT ROUSSEAU, BENOIST CHIBAU JEAN-BA CHRISTO THIERRY AN DEL,PTISTE BACHET, ANNETTE K. LARSEN,PHE TOURNIGAND, CHRISTOPHE LOUVET,DRE\u00b4 , AND AIMERY DE GRAMONT24. Gene Profiling in Early Stage Disease ........ 158RACHEL MI HAITHAM AL SALAMA, AN DGLEY, KAKIL RASUL,D DAVID J. KERR25. Chemotherapy for Colon Cancer..............162 Optimal Delivery of CytotoxicLAURA RAFTERY AN D RICHARD M. GOLDBERG26. Growth Factor Therapies with Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer..................................168 Integration of Anti-Vascular EndothelialSUILANE COELHO RIBEIRO OLIVEIRA, KARIME KALIL MACHA P DO, JORGE SABBAGA, ANDAULO M. HOFF27. Receptor Therapies with Cytotoxic Chemotherapy......................................174 Integration of Anti-Epidermal Growth FactorCE\u00b4 SAR SERRANO, BEN MARKMAN, AN DJOSE P TABERNERO28. Colorectal Cancer..................................183 Treatment of Liver-Limited MetastaticJOLEEN M. HUBBAR D AND STEVEN R. ALBERTS29. with Colorectal Cancer...........................189 Chemotherapy for the Elderly PatientD EREK G. POWER AND STUART M. LICHTMAN30. Cancer.................................................201 Combined Modality Therapy for RectalBRUCE D. MINSKY, CLAUS RO\u00a8 EDEL, ANDVINCENZO VALENTINI 31. Metastatic Colorectal Cancer...................210 Molecular Markers in the Treatment ofP ETER M. WILSON, MELISSA J. LABONTE, ANDHEINZ-JOSEF LENZ 32. Metastatic Colorectal Cancer...................221 Novel Agents in the Treatment ofSTE AIK CHOON TAN, AN PHEN LEONG, WELLS A. MESSERSMITH,D S. GAIL ECKHARDTP IMMUNOTHERA ART 4:PY OF CANCER33. of Cancer.............................................231 Introduction for ImmunotherapyJEFFREY S. WEBER 34. Chemoimmunotherapy...........................232LEISHA A. EMENS 35. Cellular Vaccine Approaches ................... 241D UNG T. LE, DREW M. PARDOLL, ANDELIZABETH M. JAFFEE 36. the Next Advance? ................................ 248 Immune Regulatory Antibodies: Are TheyJE DD D. WOLCHOK, ARVIN S. YANG, ANDJEFFREY S. WEBER 37. Relevant?.............................................255 Dendritic Cells: Are They ClinicallyKAROLINA JOSE PALUCKA, HIDEKI UENO, LEE ROBERTS,PH FAY, AND JACQUES BANCHEREAU38. Redirected to the Site of the Tumor?.........262 Chemokines: Can Effector Cells BeSTEVEN M. AN DUBINETT, JAY M. LEE, SHERVEN SHARMA,D JAMES J. MUL\u00b4E39. to Redirect Effector Cell Specificity...........273 Adoptive Cell Therapy: Genetic ModificationRICHAR D A. MORGAN, MARK E. DUDLEY, ANDSTEVEN A. ROSENBERG 40. Suppression of T-Cell Immunity...............280 Regulatory T Cells: OvercomingTATIANA N. GOLOVINA AN D ROBERT H. VONDERHEIDE41. in Human Cancer..................................286 Myeloid-Derived Suppressor CellsSRINIVAS NAGARAJ AN D DMITRY I. GABRILOVICH42. Immune Suppressor?..............................292 Indoleamine 2,3-Dioxygenase: Is It anHATEM SOLIMAN, MELANIE ME DIAVILLA-VARELA, ANDSCOTT ANTONIA 43. Inhibition and Immunotherapy in Melanoma............................................298 Interface of Signal TransductionAMBER L. SHA DA, KERRINGTON R. MOLHOEK, ANDCRAIG L. SLINGLUFF, JR. 44. T-Cell Clones........................................305 Adoptive Therapy Using Antigen-SpecificCASSIAN YEE 45. Use in Adoptive Immunotherapy..............312 Artificial Antigen-Presenting Cells forCAMERON J. TURTLE AN D STANLEY R. RIDDELL46. Good Adjuvants?...................................320 Toll-Like Receptor Agonists: Are TheySACHA GNJATIC, NIKHIL B. SAWHNEY, AN DNINA BHAR DWAJ47. Candidate Immune Modulators in Immune Therapies for Cancer ............................. 330 Novel Gamma-Chain Cytokines asNATASHA M. FEWKES AN D CRYSTAL L. MACKALL48. Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy..........................337 Gene Signature in Melanoma Associated withTHOMAS F. GAJEWSKI, JAMILA LOUAHE D, ANDVINCENT G. BRICHAR DP THE ROLE OF THE ONCOLOGIST IN ART 5:P ALLIATIVE CARE49. Palliative Care.......................................343 The Role of the Oncologist inNATHAN CHERNY 50. Palliative Care.......................................344 The Oncologist\u2019s Role in DeliveringNATHAN CHERNY 51. Teams Improve Outcomes for Cancer Patients and Their Families?....................355 What Is the Evidence That Palliative CareIRENE J. HIGGINSON AN D CATHERINE J. EVANS52. Oncology Settings..................................367 Standards for Palliative Care Delivery inS. YOUSUF ZAFAR, CHRISTO DAVID C. CURROW,PHER K. DAUGHERTY, ANDAMY P. ABERNETHY53. Tools in Routine Oncology Practice..........375 Utility and Use of Palliative Care ScreeningAMY D P. ABERNETHY, JANE L. WHEELER, ANDAVID C. CURROW54. Realism ............................................... 392 Discussing Prognosis: Balancing Hope andTOBY C. CAM BIREN SARAIYA, HOLLY B. YANG, ANTHONY L. BACK, AN PBELL, ELISE C. CAREY, VICKI A. JACKSON,D ROBERT M. ARNOLD55. and When Is It Not?...............................397 Palliative Chemotherapy: When Is It Worth ItKEITH M. SWETZ AN D THOMAS J. SMITH56. and When Is It Not?...............................403 Palliative Radiotherapy: When Is It Worth ItSTE LULUEL KHAN, E PHEN LUTZ, TIMOTHY KORYTKO, JANET NGUYEN,DWARD CHOW, AND BENJAMIN CORN57. They Worth It and When Are They Not?...412 Invasive Palliative Interventions: When AreFLORIAN STRASSER, D DAVID BLUM, ANDANIEL BUECHE58. Working with a Palliative Care Team........417LAUREN A. WIEBE AN D JAMIE H. VON ROENN59. Depression, Anxiety, and Demoralization with Advanced Cancer .................................. 422 The Oncologist\u2019s Role in ManagingSIMON WEIN, AARON SULKES, AN DSALOMON STEMMER 60. Advanced Cancer .................................. 429 Evidence-Based Approaches to Pain inSY DNEY MORSS DY61. Symptoms in Advanced Cancer................436 Evidence-Based Approaches to OtherSY DNEY MORSS AND COLLEEN C. APOSTOL62. Emergencies in Palliative Care..................442D IRK SCHRIJVERS, AND FRANK VAN FRAEYENHOVE63. Treatment Options When Chemotherapy Has Failed............................................449 Communication Skills for DiscussingBIREN SARAIYA, ROBERT ARNOL D, ANDJAMES A. TULSKY 64. with Advanced Cancer ........................... 452 Maintaining the Will to Live of PatientsLULUEL KHAN, REBECCA WONG, MA CAMILLA ZIMMERMANN, CHRIS LO, LUCIA GAGLIESE, AN DELINE LI,D GARY RODIN65. Dying Cancer Patient .............................460 The Oncologist\u2019s Role in Care of theJU DITH LACEY AND CHRISTINE SANDERSONP IM CANCER ART 6:PACT OF HEALTH CARE REFORM ONPATIENTS66. Impact on Childhood Cancer Patients and Survivors ............................................. 471 Health Care Reform 2010: Expected FavorableJULIE WOLFSON, KATHLEEN RUCCIONE, AN DGREGORY H. REAMAN 67. Care Act of 2010 on Cancer in Young Adults in the United States................................479 Potential Favorable Impact of the AffordableW. ARCHIE BLEYER 68. Act: How Will It Affect Private Health Insurance for Cancer Patients?.................488 The Patient Protection and Affordable CareKARYN SCHWARTZ AN D GARY CLAXTON69. Uninsured and Medicaid-Insured Cancer Patients................................................492 Impact of Health Care Reform Legislation onKATHERINE S. VIRGO, ELIZABETH A. BURKHAR VILMA COKKINI DT,DES, AND ELIZABETH M. WARD70. Medicare and Dual Medicare–Medicaid Beneficiaries .........................................499 Impact of Health Care Reform onKENNETH E. THOR PE AND MEREDITH PHILYAW71. Act: Exploring the Potential Impact on Oncology Practice ................................. 503 The Patient Protection and Affordable CareJOSE PH S. BAILES, DEBORAH Y. KAMIN, ANDSHELAGH E. FOSTER 72. The Intersection of Health Care Reform, Primary Care Providers, and Cancer Patients .....................................508 An Opportunity for Coordinated Cancer Care:LAUREN G. COLLINS, RICHAR D WENDER, ANDMARC ALTSHULER 73. Patient: A View from Cancer Executives....514 Impact of Healthcare Reform on the CancerLIN TERI URSIN GUI DA W. FERRIS, MATTHEW FARBER,DI, AND WILLIAM J. LAFFEY74. of PPACA on Cancer Research.................520 The Anticipated and Unintended ConsequencesSTE D PHEN B. EDGE, LEONARD A. ZWELLING, ANDAVID C. HOHN75. Diagnosis Among Patients Aged 55 to 74 Years in the National Cancer Database..............527 The Association of Insurance and Stage atELIZABETH M. WAR VILMA COKKINI D, STACEY A. FEDEWA,DES, AND KATHERINE VIRGO76. ObamaCare: Miscalculated Assurances ..... 534ROGER M. BATTISTELLA 77. Legislation ........................................... 540 Concerns Presented by the New HealthSTUART M. BUTLER Index 545